Unitaid audited financial report for the year ended 31 December 2022
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Overview of mpox antivirals and diagnostics landscape
Next generation pulse oximeters technology and market landscape
Malaria diagnostics market and technology landscape
Landscape of innovative tools and delivery strategies for eliminating vertical transmission of HIV, syphilis, hepatitis B, and chagas in endemic areas
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2021 Report (May 2018)
Fever Diagnostic Technology Landscape
Multi-disease diagnostics landscape for integrated management of HIV, HCV, TB and other coinfections
Hepatitis C medicines technology and market landscape
Unitaid’s approach to intellectual property
Discussion Paper: Ensuring that essential medicines are also affordable medicines: challenges and options
Discussion Paper: An economic perspective on delinking the cost of R&D from the price of medicines
Unitaid audited financial report for the year ended 31 December 2021
Unitaid audited financial report for the year ended 31 December 2020
Unitaid audited financial report for the year ended 31 December 2019
Unitaid audited financial report for the year ended 31 December 2018
Financial Guidelines for Unitaid Grant Implementers (Frequently Asked Questions)
Unitaid 2017-2021 Strategy Review, Management Response, Dec 2021
Unitaid 2017-2021 Strategy Review, Final Report, Vol 2, Annexes
Unitaid 2017-202 Strategy Review, Final Report, Vol 1, Main report
Financial guidelines for Unitaid grant implementers
Financial Guidelines for Unitaid Grantees
Landscape for HIV rapid diagnostic tests for HIV self-testing – 2020
Impact story: Paving the way to hepatitis C elimination
